| Features: |
| Gambogic acid is a naturally occurring xanthonoid extracted from the resin of trees belonging to the Garcinia genus—most notably, Garcinia hanburyi. This tree is native to regions in Southeast Asia, particularly found in areas of China, India, and neighboring countries. Gambogic acid (GA; C38H44O8, MW: 628.76), a polyprenylated xanthone and a widely used coloring agent, is the main active ingredient of gamboges secreted from the Garcinia hanburyi tree ([3, 4], which mainly grows in Southeast Asia. GA has been approved by the Chinese FDA for the treatment of solid cancers in Phase II clinical trials. Pathways: -evidence suggesting that it can inhibit thioredoxin reductase (TrxR). -can indeed lead to an increase in reactive oxygen species (ROS) levels -Gambogic acid can trigger mitochondrial dysfunction, leading to cytochrome c release -influences death receptors -Inhibition of NF-κB Signaling -Inhibition of VEGF Pathway -Cell Cycle Arrest: -p53 Activation |
| 2703- | BBR, | CUR, | SFN, | UA, | GamB | Naturally occurring anti-cancer agents targeting EZH2 |
| - | Review, | Var, | NA |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
| 2426- | GamB, | Anti-cancer natural products isolated from chinese medicinal herbs |
| - | Review, | Var, | NA |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1973- | GamB, | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain |
| - | in-vitro, | Liver, | SMMC-7721 cell |
| 1972- | GamB, | doxoR, | Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression |
| - | in-vitro, | BC, | NA |
| 1971- | GamB, | Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vivo, | NA, | NA |
| 1970- | GamB, | Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway |
| - | NA, | Lung, | NCI-H441 |
| 1969- | GamB, | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| - | in-vitro, | Lung, | A549 |
| 1967- | GamB, | Gambogic acid induces apoptotic cell death in T98G glioma cells |
| - | in-vitro, | GBM, | T98G |
| 1966- | GamB, | Cisplatin, | Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | NCIH1299 |
| 1954- | GamB, | Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 1964- | GamB, | Gambogic acid suppresses the pentose phosphate pathway by covalently inhibiting 6PGD protein in cancer cells |
| - | in-vitro, | NA, | NA |
| 1963- | GamB, | Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model |
| - | in-vitro, | Lung, | NA |
| 1962- | GamB, | HCQ, | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
| - | in-vitro, | PC, | NA |
| 1961- | GamB, | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 1960- | GamB, | Vem, | Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 1956- | GamB, | Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis |
| - | in-vitro, | Melanoma, | A375 |
| 1955- | GamB, | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
| - | in-vitro, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:302 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid